Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Peripheral Neuropathy of Paclitaxel in Second-line Chemotherapy for Gastric Cancer

NCT06490159 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06490159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06490159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Peripheral Neuropathy of Paclitaxel in Second-line Chemotherapy for Gastric Cancer
Lead sponsor
City of Hope Medical Center
Phase
Observational
Overall status
Recruiting
Start date
October 1, 2018
Completion date
June 18, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced peripheral neuropathy, gastric cancer, paclitaxel, ramucirumab